06660 AIM VACCINE
- 8.390
- +0.110+1.33%
AIM VACCINE News
Le Méridien Vaccine (06660.HK) received 400 additional H shares by Zhou Yan, worth approximately HK$3,328
On May 3, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 3, Zhou Yan increased her H shares of $Aimei Vaccine (06660.HK) by $400 at an average price of HK$8.32 per share on April 26, worth about HK$3,328. After the increase in holdings, Zhou Yan's latest shareholding was 24.5816 million shares, with a good position ratio of 4.99%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors and top executives of listed companies are required
艾美疫苗：2023年度報告
Le Méridien Vaccine (06660.HK) received 6,400 additional H shares by Zhou Yan, worth approximately HK$53,800
On April 19, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 19, Zhou Yan increased her H shares of $Aimei Vaccine (06660.HK) by $6,400 at an average price of HK$8.404 per share on April 15, worth about HK$53,800. After the increase in holdings, Zhou Yan's latest shareholding was 24.5812 million shares, with a good position ratio of 4.99%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors and top administration of listed companies
Le Méridien Vaccine (06660.HK) Voluntary Announcement: Controlling Shareholder Continues to Further Increase H Shares
Gelonghui, April 18, 丨 Le Méridien Vaccine (06660.HK) announced that the company's board of directors received a notice from Zhou Yan (Chairman of the Board, Executive Director, CEO and controlling shareholder of the company). Zhou Yan continued to further increase the company's H shares through the open market from January 22, 2024 to April 18, 2024. From November 14, 2023 to April 18, 2024, Zhou Yan has continued to increase her H shares in the company through the open market with total capital of HK$10,420,212.00, and it is not ruled out that she will continue to increase her shares in due course. As of this announcement
R&D investment in the Le Méridien vaccine has been growing rapidly in recent years. In 2024, three major iteratively upgraded vaccines will be declared and launched
Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3%
Aim Vaccine (HKG:6660) submitted pre-applications for clinical trials for two vaccines on Thursday, according to two separate Hong Kong bourse filings on the same day. These include the quadrivalent i
Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3%
Aim Vaccine (HKG:6660) booked an attributable loss of 1.3 billion yuan in 2023, up 307.1% from 319.6 million yuan the prior year, according to a Thursday Hong Kong bourse filing. Loss per share for th
R&D expenses surged 27% in 2023, and the Emmy vaccine is intensively declaring a major iterative upgrade vaccine
The three major iterative upgraded vaccines of the Emmy vaccine have been declared for sale this year, and the international market layout has already begun
GLONGHUI, March 28 | Le Méridien Vaccine (6660.HK) today announced the 2023 fiscal year results report. R&D expenses during the period exceeded 636 million yuan, an increase of 27.2% over the previous year. This year, 3 major iteratively upgraded vaccines were declared for sale, and 7 were declared clinical. By the end of 2023, Le Méridien had obtained 14 clinical approvals, conducted 21 clinical trials, and 5 were in phase III clinical completion. Currently, three major iteratively upgraded vaccines, including the 13-valent pneumonia conjugate vaccine, the serum-free iterative rabies vaccine, and the 23-valent pneumopolysaccharide vaccine, have completed marketing declarations this year, which are expected to bring significant benefits to the company's performance as soon as possible
Le Méridien vaccine (06660): quadrivalent MDCK cell influenza virus vaccine submitted for clinical trial pre-application
Le Méridien Vaccine (06660) announced that the group submitted quadrivalent MDCK cells on March 27, 2024...
Aimei Vaccine (06660) has submitted a pre-application for clinical trials of Haemophilus influenzae type b (Hib) conjugate vaccine
The Le Méridien vaccine (06660) was announced. The group submitted Haemophilus influenzae type b (H...
The Le Méridien vaccine (06660) has entered a major year of intensive reporting, and the mRNA technology platform lays out multiple popular vaccines
The Zhitong Finance App learned that on March 28, Emmy Vaccine (06660) released the 2023 results and several major new product development announcements. The data...
AIM VACCINE: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Aim Vaccine Submits Clinical Trial's Pre-Application for Rabies Vaccine
Aim Vaccine Co (HKG:6660) submitted the pre-application for clinical trials of its new rabies vaccine, according to a Tuesday Hong Kong bourse filing. The vaccine maker said it has developed a novel,
Another major iterative upgrade of the rabies vaccine submitted for clinical trials, and the Le Méridien vaccine (06660) has entered a major reporting year
The Zhitong Finance App learned that the Emmy Vaccine (06660) announced on the evening of the 26th that the company has recently submitted a pre-clinical trial application for a novel, high-cost human diploid rabies vaccine. This is another major milestone in Emmy Vaccine's promotion of mad vaccine development according to the established strategy after the layout of the iterative upgrade series of rabies vaccines was completed at the beginning of this month. Major manufacturers of Mad Miao are making efforts to lead the global industry's in-depth technological iterative upgrading. According to the announcement, Le Méridien's novel process is an efficient and affordable human diploid rabies vaccine, which has many innovative points. It was the first to break through the traditional technical bottleneck of the low virus titer and low yield of this process, and carried it out in the purification process
Le Méridien Vaccine (06660): Novel Process and Highly Effective Human Diploid Rabies Vaccine Submits Pre-Application for Clinical Trials
Le Méridien Vaccine (06660) announced that on March 24, 2024, the group submitted a novel process with high cost efficiency 2...
CMB International Finance Limited sold 6.8716 million H shares of Le Méridien Vaccine (06660.HK), worth approximately HK$84.5534 million
On March 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 25, on October 9, 2023, CMB International Finance Limited sold $6.87016 million H shares worth HK$6.881 million (06660.HK) at an average price of HK$11.7081 per share. After the sale, the latest number of shares held by CMB International Finance Co., Ltd. was 33.584 million shares, and the good position ratio dropped from 7.56% to 6.17%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, the majority shareholder (holding 5% of the shares or
CMB International Finance Limited sold 829,000 H shares of Le Méridien Vaccine (06660.HK), worth approximately HK$9.821 million
On March 25, it was reported that, according to documents disclosed by the Hong Kong Stock Exchange on March 25, 2023, CMB International Finance Limited sold $829,000 H shares worth HK$9.821 million at an average price of HK$11.9085 per share. After the sale, the latest number of shares held by CMB International Finance Co., Ltd. was 29.031 million shares, and the good position ratio dropped from 6.07% to 5.90%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (those holding 5% or more of the shares)
One AIM Vaccine Insider Raised Stake By 27% In Previous Year
From what we can see, insiders were net buyers in AIM Vaccine Co., Ltd.'s (HKG:6660 ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. While ins
CMB Financial Holdings (Shenzhen) Co., Ltd. sold 829,000 H shares of Le Meridien Vaccine (06660.HK), worth approximately HK$9.821 million
On March 22, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 22, CMB Financial Holdings (Shenzhen) Limited sold $829,000 H shares worth HK$9.821 million at an average price of HK$11.9085 per share on October 11, 2023. After the sale, the latest number of shares held by CMB Financial Holdings (Shenzhen) Co., Ltd. was 29.031 million shares, and the good position ratio dropped from 6.07% to 5.90%. This transaction involves other related parties: CMB International Financial Holdings Limited and CMB International Capital Management (Shenzhen)
Analysis
Price Target
No Data
